JP2021502980A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502980A5 JP2021502980A5 JP2020526482A JP2020526482A JP2021502980A5 JP 2021502980 A5 JP2021502980 A5 JP 2021502980A5 JP 2020526482 A JP2020526482 A JP 2020526482A JP 2020526482 A JP2020526482 A JP 2020526482A JP 2021502980 A5 JP2021502980 A5 JP 2021502980A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cancer
- antibody
- seq
- atpase activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 14
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 10
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 9
- 108091006112 ATPases Proteins 0.000 claims 7
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 229910052697 platinum Inorganic materials 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 101100501552 Homo sapiens ENTPD1 gene Proteins 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical group O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102220473342 Connector enhancer of kinase suppressor of ras 1_E143A_mutation Human genes 0.000 claims 1
- 101710116102 Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102220556031 Methylthioribulose-1-phosphate dehydratase_Q96A_mutation Human genes 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102220485195 Testis-expressed protein 30_N99A_mutation Human genes 0.000 claims 1
- 102220498085 Transcriptional adapter 2-alpha_R147E_mutation Human genes 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102220481538 eIF5-mimic protein 2_K87A_mutation Human genes 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 102000053350 human FCGR3B Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229950007221 nedaplatin Drugs 0.000 claims 1
- 190000005734 nedaplatin Chemical compound 0.000 claims 1
- 229950005566 picoplatin Drugs 0.000 claims 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 229960005399 satraplatin Drugs 0.000 claims 1
- 190014017285 satraplatin Chemical compound 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762586224P | 2017-11-15 | 2017-11-15 | |
| US62/586,224 | 2017-11-15 | ||
| US201862686149P | 2018-06-18 | 2018-06-18 | |
| US62/686,149 | 2018-06-18 | ||
| US201862733175P | 2018-09-19 | 2018-09-19 | |
| US62/733,175 | 2018-09-19 | ||
| PCT/EP2018/081364 WO2019096900A1 (en) | 2017-11-15 | 2018-11-15 | Potentiating the effect of atp release |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502980A JP2021502980A (ja) | 2021-02-04 |
| JP2021502980A5 true JP2021502980A5 (enExample) | 2021-07-26 |
| JP7383609B2 JP7383609B2 (ja) | 2023-11-20 |
Family
ID=64332078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526482A Active JP7383609B2 (ja) | 2017-11-15 | 2018-11-15 | Ａｔｐ放出の効果の強力化 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190218304A1 (enExample) |
| EP (1) | EP3710052A1 (enExample) |
| JP (1) | JP7383609B2 (enExample) |
| KR (1) | KR102781619B1 (enExample) |
| CN (1) | CN111372606B (enExample) |
| AU (1) | AU2018368541B2 (enExample) |
| BR (1) | BR112020009655A8 (enExample) |
| CA (1) | CA3075371A1 (enExample) |
| IL (1) | IL273440A (enExample) |
| SG (1) | SG11202002195YA (enExample) |
| WO (1) | WO2019096900A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2238170T (pt) | 2008-01-31 | 2017-02-21 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Anticorpos contra cd39 humano e seu uso para inibição da actividade de células t reguladoras |
| IL269150B2 (en) | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| WO2018209324A2 (en) | 2017-05-11 | 2018-11-15 | The Broad Institute, Inc. | Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| JP7113071B2 (ja) | 2017-07-31 | 2022-08-04 | トリシュラ セラピューティクス， インコーポレイテッド | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
| SG11202002192QA (en) * | 2017-10-06 | 2020-04-29 | Innate Pharma | Restoration of t cell activity via the cd39/cd73 axis |
| MX2020011588A (es) | 2018-05-03 | 2020-12-07 | Shanghai Epimab Biotherapeutics Co Ltd | Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. |
| TWI870353B (zh) | 2018-06-18 | 2025-01-21 | 法商天賜製藥公司 | 用於治療癌症之組合物及方法 |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| TW202118791A (zh) | 2019-11-05 | 2021-05-16 | 大陸商北京加科思新藥研發有限公司 | 對cd39具有特異性的結合分子及其用途 |
| KR102856075B1 (ko) | 2020-07-17 | 2025-09-04 | 삼성전자주식회사 | 비휘발성 메모리 장치 및 그 동작 방법 |
| CN115975030B (zh) * | 2021-09-30 | 2023-09-26 | 杭州邦顺制药有限公司 | 抗cd39抗体-药物偶联物及其用途 |
| CN119569881B (zh) | 2022-03-03 | 2025-11-07 | 艾库斯生物科学有限公司 | 抗cd39抗体及其用途 |
| US20250188165A1 (en) * | 2022-03-04 | 2025-06-12 | Trishula Therapeutics Inc | Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
| PT2238170T (pt) | 2008-01-31 | 2017-02-21 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Anticorpos contra cd39 humano e seu uso para inibição da actividade de células t reguladoras |
| US10766966B2 (en) * | 2014-10-10 | 2020-09-08 | Innate Pharma | CD73 blockade |
| EP3215538A4 (en) * | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| US20190153113A1 (en) * | 2015-11-23 | 2019-05-23 | Innate Pharma | Cd39 vascular isoform targeting agents |
| EP3912681A1 (en) | 2016-03-14 | 2021-11-24 | Orega Biotech | Anti-cd39 antibodies |
| IL269150B2 (en) * | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| KR102495666B1 (ko) * | 2018-03-14 | 2023-02-06 | 서피스 온콜로지, 인크. | Cd39에 결합하는 항체 및 이의 용도 |
-
2018
- 2018-11-15 CN CN201880070859.6A patent/CN111372606B/zh active Active
- 2018-11-15 EP EP18803967.1A patent/EP3710052A1/en active Pending
- 2018-11-15 BR BR112020009655A patent/BR112020009655A8/pt unknown
- 2018-11-15 JP JP2020526482A patent/JP7383609B2/ja active Active
- 2018-11-15 KR KR1020207013452A patent/KR102781619B1/ko active Active
- 2018-11-15 WO PCT/EP2018/081364 patent/WO2019096900A1/en not_active Ceased
- 2018-11-15 CA CA3075371A patent/CA3075371A1/en active Pending
- 2018-11-15 AU AU2018368541A patent/AU2018368541B2/en active Active
- 2018-11-15 SG SG11202002195YA patent/SG11202002195YA/en unknown
-
2019
- 2019-03-29 US US16/370,789 patent/US20190218304A1/en not_active Abandoned
-
2020
- 2020-03-19 IL IL273440A patent/IL273440A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502980A5 (enExample) | ||
| JP7564172B2 (ja) | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 | |
| AU2019396895B2 (en) | Combination of antibody-drug conjugate with PARP inhibitor | |
| TWI826690B (zh) | 經取代之烯吲哚酮化物及其用途 | |
| BR112020025715A2 (pt) | Ligantes de peptídeo bicíclico específico para nectina-4 | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| CN114245807A (zh) | Flt3l-fc融合蛋白和使用方法 | |
| JP2019527706A5 (enExample) | ||
| CN106132991A (zh) | 针对tim‑3的抗体分子及其用途 | |
| MX2014001370A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| JP2020513809A5 (enExample) | ||
| JP2016530323A5 (enExample) | ||
| RS58535B1 (sr) | Molekuli antitela protiv pd-1 i njihove upotrebe | |
| MX2014001375A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2021534757A (ja) | アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド | |
| IL274160B2 (en) | Methods and compositions for dosing allogeneic chimeric T cells for antigen receptors | |
| CN108883109A (zh) | 用于治疗急性髓性白血病的联合疗法 | |
| CN116529360A (zh) | 用于刺激γδT细胞的方法和组合物 | |
| JP2023548831A (ja) | 腫瘍溶解性ウイルスが有効なｔｉｌ療法のためにｔ細胞応答を強化する | |
| JP2009510165A5 (enExample) | ||
| Tsukasaki et al. | Clinical trials and treatment of ATL | |
| JP7715041B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| TW202305000A (zh) | 表現抗ror1/抗cd3雙特異性抗體之溶瘤病毒 | |
| US20230139178A1 (en) | Medicament for treatment and/or prevention of cancer | |
| CA2824417C (en) | Mycobacterium w for use in treating cancer |